Serious ED (IIEF score 1sirtuininhibitor0), n ( ) ED duration sirtuininhibitor3 months, n ( ) 3sirtuininhibitor6 months, n ( ) 6sirtuininhibitor12 months, n ( ) !12 months, n ( ) Etiology of ED Organic Psychogenic Mixed Unknown International Index of Erectile Function (IIEF) Imply IIEF-EF (SD) Imply IIEF-IS (SD) 17.85 (8.48) 7.89 (three.74) 17.52 (eight.51) 7.89 (3.79) (Continued) 206 (27.six) 26 (three.five) 225 (30.1) 117 (15.7) 195 (25.9) 25 (3.3) 258 (34.three) 107 (14.2) 5 (0.9) 15 (two.6) 57 (9.9) 497 (86.6) five (0.9) 16 (2.7) 61 (10.four) 503 (86.0) 574 (76.9) 147/574 (25.6) 340/574 (59.2) 87/574 (15.2) 585 (77.eight) 148/585 (25.3) 339/585 (57.9) 98/585 (16.eight) 205 (27.four) 7 (1.3) 204 (27.1) 10 (1.9) 20) 487 (65.2) 260 (34.8) 10.14 (four.23) 488 (64.9) 264 (35.1) 10.21 (three.63) 17.39 (5.95) 9.95 (four.09) 7.44 (2.96) 3.66 (1.26) five.24 (three.12) 4.04 (1.0) 17.53 (five.73) ten.14 (three.97) 7.39 (two.92) 3.60 (1.27) 5.09 (three.02) 3.99 (0.97) 650 (87.0) 49 (six.six) 16 (two.1) 232 (31.1) 28.4 (4.four) 465 (62.3) six.02 (five.43) 99 (13.3) 649 (86.three) 49 (6.five) 17 (two.3) 173 (23.0) 27.eight (four.0) 457 (60.9) 5.84 (5.64) 90 (12.0) 306 (41.0) 74 (9.9) 308 (41.0) 68 (9.0) Placebo (N = 747) Tadalafil 5mg (N = 752)PLOS A single | DOI:ten.1371/journal.pone.0135484 August 18,5 /Predictors of Response to Tadalafil in LUTS-BPHTable 1. (Continued) Traits Imply IIEF-OF (SD) Imply IIEF-OS (SD) Imply IIEF-SD (SD) Previous ED therapies (inside 12 months of screening), n ( ) PDE-5 inhibitor, n ( ) Laboratory parameters Mean PSA (SD), ng/ml Imply total testosterone (SD), ng/dl Imply totally free testosterone (SD), ng/dl Mean bioavailable testosterone (SD), ng/dl Mean bioavailable testosterone (SD) Mean albumin (SD), g/dl Mean sex hormone binding globulin (SHBG) (SD) nmol/l Comorbidities Diabetes mellitus, n ( ) Hypertension, n ( ) Hyperlipidaemia, n ( ) Vasculitis, n ( ) Ischaemic heart illness, n ( ) Myocardial infarction, n ( ) Cardiac arrhythmia, n ( ) Cardiac failure, n ( ) Cardiomyopathy, n ( ) Other cardiac issues, n ( ) Any cardiac disorder, n ( ) Haemorrhagic cerebrovascular problems, n ( ) Ischaemic cerebrovascular disorders, n ( ) Other cerebrovascular issues, n ( ) Any cerebrovascular disorder, n ( ) Peripheral vascular thrombosis or embolism, n ( ) Miscellaneous vascular disorder, n ( ) Other vascular disorder, n ( ) Cardiovascular disorder, n ( ) Renovascular disorder, n ( ) Renal impairment Glomerular filtration price (GFR) ml/min/ 1.73m2 Renal impairment stage I (GFR !90) n ( ) Renal impairment stage II (GFR 60sirtuininhibitor9) n ( ) Concomitant drugs Testosterone, n ( ) Imply quantity anti-hypertensive medications -blockers, n ( ) sirtuininhibitorblockers, n ( ) Calcium channel blockers, n ( ) Angiotensin converting enzyme inhibitors, n ( ) 1 (0.Serum Albumin/ALB Protein Biological Activity 1) 0.MCP-1/CCL2 Protein MedChemExpress 90 (1.PMID:32695810 13) 202 (27.0) 92 (12.3) 76 (10.2) 125 (16.7) 1 (0.1) 0.92 (1.07) 206 (27.four) 114 (15.two) 68 (9.0) 146 (19.4) (Continued) 199 (26.eight) 327 (44.0) 228 (30.6) 368 (49.3) 94 (12.6) 288 (38.six) 152 (20.3) 0 (0) 44 (5.9) 11 (1.5) 41 (5.5) six (0.eight) 0 (0) 19 (2.5) 97 (13.0) 7 (0.9) 11 (1.five) 1 (0.1) 11 (1.five) 18 (2.4) 20 (two.7) 309 (41.four) 342 (45.eight) 0 (0) 98 (13.0) 300 (39.9) 183 (24.3) three (0.4) 43 (five.7) 11 (1.five) 32 (4.three) five (0.7) 1 (0.1) 25 (3.three) 91 (12.1) five (0.7) 10 (1.3) 0 (0) 10 (1.3) 17 (2.three) 13 (1.7) 311 (41.four) 344 (45.7) 0 (0) 1.74 (1.51) 3.76 (1.36) 0.06 (0.02) 1.40 (0.46) 39.26 (12.07) four.22 (0.33) 40.37 (21.21) 1.87 (1.46) 3.66 (1.23) 0.06 (0.02) 1.38 (0.42) 39.70 (11.09) 4.21 (0.32) 41.02 (20.82) 167 (22.4) 173 (23.0) Placebo (N = 747) 7.03 (three.17) 5.79 (two.51) six.55 (1.